{"podcast":{"title":"The Fellow on Call: The Heme/Onc Podcast","slug":"the-fellow-on-call-the-heme-onc-podcast-4669989","podcast_index_feed_id":4669989,"rss_url":"https://www.thefellowoncall.com/tfocpodcast?format=rss","website_url":"https://www.thefellowoncall.com/tfocpodcast/","image_url":"https://images.squarespace-cdn.com/content/v1/61b273ac9be6aa2250498c9e/1641065434990-8BV6L7UFJF4JCCKCY6S1/Untitled+design+%281%29+copy.png?format=1500w","author":"Ronak Mistry","episode_count":164,"summary":"We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.","last_synced_at":"2026-06-24T18:17:58.817010+00:00","page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989"},"episode":{"title":"Episode 147: Myeloma Series, Pt. 7 - Transplant Consolidation for Multiple Myeloma (2026)","slug":"episode-147-myeloma-series-pt-7-transplant-consolidation-for-multiple-myeloma-2026","published_at":"2026-03-11T08:00:00+00:00","page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-147-myeloma-series-pt-7-transplant-consolidation-for-multiple-myeloma-2026","show_page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989","url":"https://www.thefellowoncall.com/tfocpodcast/myelomatransplantconsolidation","audio_url":"https://static1.squarespace.com/static/61b273ac9be6aa2250498c9e/t/69b06d413879085c7330cddb/1773754701025/The+Fellow+On+Call+-+MM+Consolidation+-+Mix_FinalEdit.mp3","summary":"This week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and the MIDAS Trial. Content: - What is the role of autologous stem cell transplant in the management of multiple myeloma? - How did we get to our current standards of care? - How is minimal residual disease (MRD) fitting into our treatment paradigm? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube","meta_description":"This week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and t…","key_points":[],"chapters":[],"topics":[],"duration_seconds":null,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-147-myeloma-series-pt-7-transplant-consolidation-for-multiple-myeloma-2026/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-147-myeloma-series-pt-7-transplant-consolidation-for-multiple-myeloma-2026.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}